Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy
Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.
Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished
Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.
ASCO 2026: Tubulis set to present maturing Phase I/IIa data on TUB-040 exatecan ADC in PROC
Tubulis presents updated TUB-040 Phase I/IIa data at ASCO 2026. Here is what the NAPISTAR 1-01 readout means for NaPi2b and ovarian cancer treatment.
Why Tubulis gives Gilead more than just another antibody-drug conjugate asset
Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.